Seizure as the first manifestation of transitional cell carcinoma of the renal pelvis.

brain metastasis renal pelvis urothelial carcinoma

Journal

Journal of surgical case reports
ISSN: 2042-8812
Titre abrégé: J Surg Case Rep
Pays: England
ID NLM: 101560169

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 05 04 2020
accepted: 13 04 2020
entrez: 24 7 2020
pubmed: 24 7 2020
medline: 24 7 2020
Statut: epublish

Résumé

Upper tract urothelial carcinoma (UTUC) is a rare genitourinary entity of the renal pelvis and the ureter characterized by an aggressive behavior. Cisplatin-based chemotherapy is the first-line therapy of metastatic UTUC. However, a large number of patients with metastatic UTUC are considered ineligible for cisplatin. Immunotherapy emerged as a promising treatment in this setting. Brain metastasis from UTUC is unusual, occurring most often in the presence of systemic metastases. Local therapies such as stereotactic radiosurgery, neurosurgical resection and whole-brain radiotherapy (WBRT) remain the main therapeutic options for brain metastasis. We report a case of a 65-year-old male patient presenting with generalized tonic-clonic seizure. Imaging studies confirmed the presence of multiple brain metastasis. During an evaluation for the primary, he was found to be having metastatic UTUC of the renal pelvis. The brain metastases were treated by hippocampal sparing WBRT with minimal neurotoxicity. The primary tumor was treated by pembrolizumab.

Identifiants

pubmed: 32699589
doi: 10.1093/jscr/rjaa126
pii: rjaa126
pmc: PMC7365028
doi:

Types de publication

Case Reports

Langues

eng

Pagination

rjaa126

Informations de copyright

Published by Oxford University Press and JSCR Publishing Ltd. All rights reserved. © The Author(s) 2020.

Références

World J Nephrol. 2016 Mar 6;5(2):158-65
pubmed: 26981440
Oncotarget. 2017 Jan 10;8(2):3568-3580
pubmed: 27683040
Ther Adv Urol. 2019 Jan 08;11:1756287218815372
pubmed: 30671136
J Clin Oncol. 2015 Oct 20;33(30):3475-84
pubmed: 26282648
J Comput Assist Tomogr. 2011 Mar-Apr;35(2):217-22
pubmed: 21412093
Int Urol Nephrol. 2007;39(3):747-50
pubmed: 17203346
Cancer Manag Res. 2019 May 15;11:4519-4528
pubmed: 31191013
Neurosurg Clin N Am. 1996 Jul;7(3):337-44
pubmed: 8823767
J Radiosurg SBRT. 2014;3(2):111-121
pubmed: 29296392
Surg Neurol Int. 2013 May 02;4(Suppl 4):S203-8
pubmed: 23717791

Auteurs

Mohamad Moussa (M)

Head of Urology Department, Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon.

Mohamed Abou Chakra (MA)

Department of Urology, Faculty of Medicine, Lebanese University, Beirut, Lebanon.

Baraa Dabboucy (B)

Department of Neurosurgery, Faculty of Medicine, Lebanese University, Beirut, Lebanon.

Athanasios G Papatsoris (AG)

2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Youssef Fares (Y)

Department of Neurosurgery, Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.

Classifications MeSH